Visual Acuity and ERG Findings After Bevacizumab Injection in Premature Infants
Author Information
Author(s): Shah Parag K, Morris Rodney J, Narendran V, Kalpana N
Primary Institution: Aravind Eye Hospital and Postgraduate Institute of Ophthalmology
Hypothesis
Does intravitreal injection of bevacizumab affect visual acuity and electroretinography in infants with aggressive posterior retinopathy of prematurity?
Conclusion
Intravitreal bevacizumab does not adversely affect electroretinography but may impact final visual acuity.
Supporting Evidence
- Bevacizumab injection led to dramatic improvement in anterior segment ischemia.
- Visual acuity improved to 20/30 in the right eye but remained poor in the left eye.
- Electroretinography showed extensive damage to rods and bipolar cells.
Takeaway
A baby with a serious eye condition got a special eye injection, and while it helped some things, it didn't make his vision as good as hoped.
Methodology
The study involved a case report of a single infant who received an intravitreal injection of bevacizumab and was followed up for visual acuity and ERG findings.
Potential Biases
Potential bias due to the lack of a control group and reliance on a single case report.
Limitations
The study is based on a single case, limiting the generalizability of the findings.
Participant Demographics
A male infant born at 31 weeks of gestation with a birth weight of 1170 g.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website